JP2024510274A5 - - Google Patents
Info
- Publication number
- JP2024510274A5 JP2024510274A5 JP2023557092A JP2023557092A JP2024510274A5 JP 2024510274 A5 JP2024510274 A5 JP 2024510274A5 JP 2023557092 A JP2023557092 A JP 2023557092A JP 2023557092 A JP2023557092 A JP 2023557092A JP 2024510274 A5 JP2024510274 A5 JP 2024510274A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- optionally substituted
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/081177 | 2021-03-16 | ||
| CN2021081177 | 2021-03-16 | ||
| PCT/CN2021/106028 WO2022193499A1 (en) | 2021-03-16 | 2021-07-13 | Amino heteroaryl compounds and compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024510274A JP2024510274A (ja) | 2024-03-06 |
| JP2024510274A5 true JP2024510274A5 (cg-RX-API-DMAC7.html) | 2024-07-23 |
Family
ID=83321944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557092A Pending JP2024510274A (ja) | 2021-03-16 | 2021-07-13 | アミノヘテロアリール化合物および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240246944A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4308556A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024510274A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117083268B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213816A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022193499A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| TWI925948B (zh) * | 2021-02-06 | 2026-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 含聯環的tyk2抑制劑化合物、藥物組合物及其用途 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| US20260098017A1 (en) * | 2022-12-24 | 2026-04-09 | Tianjin Pharmaceutical Biotechnology Co., Ltd. | Novel aromatic ring derivative containing amide substitution and use thereof |
| WO2024174229A1 (en) * | 2023-02-24 | 2024-08-29 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Covalent binding compounds and compositions |
| CN116162093B (zh) * | 2023-04-25 | 2023-06-23 | 中南大学湘雅医院 | 一种tyk2抑制剂化合物及其用途 |
| CN117624126B (zh) * | 2023-12-05 | 2026-01-30 | 中国药科大学 | 选择性酪氨酸激酶2(tyk2)抑制剂化合物、合成方法及用途 |
| WO2025186427A1 (en) | 2024-03-08 | 2025-09-12 | Curia Spain, S.A.U. | Process for the preparation of deucravacitinib and intermediates thereof and method for purifying deucravacitinib |
| WO2025255092A1 (en) * | 2024-06-03 | 2025-12-11 | Artax Biopharma Inc. | Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| AR094537A1 (es) | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| KR102782807B1 (ko) | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| US10836770B2 (en) | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| US11299494B2 (en) | 2016-11-17 | 2022-04-12 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators |
| MA48602A (fr) | 2016-12-13 | 2020-03-18 | Bristol Myers Squibb Co | Composés hétéroaryle substitués par un amide alkyle d'oxyde de phosphine en tant que modulateurs des réponses il-12, il-23 et/ou ifn alpha |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| MY202167A (en) | 2017-11-21 | 2024-04-12 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| JP7485609B2 (ja) | 2018-03-22 | 2024-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | IL-12、IL-23および/またはIFNα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 |
| EP3849981B1 (en) | 2018-09-10 | 2023-02-01 | Eli Lilly and Company | Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Tyk2阻害剤およびその使用 |
| RS66346B1 (sr) * | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| KR102858043B1 (ko) * | 2018-10-30 | 2025-09-10 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 조정과 관련된 상태의 치료를 위한 아미드-치환된 헤테로시클릭 화합물 |
| WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| TWI800696B (zh) | 2018-12-10 | 2023-05-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物 |
| KR102943760B1 (ko) | 2019-01-28 | 2026-03-26 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도 |
| CN111484480B (zh) * | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| WO2020159904A1 (en) * | 2019-01-30 | 2020-08-06 | Bristol-Myers Squibb Company | Amide-disubstituted pyridine or pyridazine compounds |
| CN111909140A (zh) | 2019-04-12 | 2020-11-10 | 明慧医药(杭州)有限公司 | 作为tyk2抑制剂的杂环化合物及合成和使用方法 |
| KR20230004771A (ko) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
-
2021
- 2021-07-13 EP EP21931081.0A patent/EP4308556A4/en active Pending
- 2021-07-13 CA CA3213816A patent/CA3213816A1/en active Pending
- 2021-07-13 CN CN202180095847.0A patent/CN117083268B/zh active Active
- 2021-07-13 WO PCT/CN2021/106028 patent/WO2022193499A1/en not_active Ceased
- 2021-07-13 JP JP2023557092A patent/JP2024510274A/ja active Pending
- 2021-07-13 US US18/550,898 patent/US20240246944A1/en active Pending